hVIVO Past Earnings Performance
Past criteria checks 3/6
hVIVO has been growing earnings at an average annual rate of 77%, while the Life Sciences industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 31.4% per year. hVIVO's return on equity is 23.8%, and it has net margins of 16.1%.
Key information
77.04%
Earnings growth rate
81.51%
EPS growth rate
| Life Sciences Industry Growth | 36.86% |
| Revenue growth rate | 31.36% |
| Return on equity | 23.84% |
| Net Margin | 16.09% |
| Last Earnings Update | 31 Dec 2024 |
Recent past performance updates
Recent updates
Expansion Into New Canary Wharf Facility Will Increase Capacity But Challenges In Sustaining Margins May Arise
Feb 09 Expansion into a new facility and offering new services are expected to drive revenue growth and diversify income streams.hVIVO plc's (LON:HVO) Intrinsic Value Is Potentially 28% Above Its Share Price
Jan 26
Improved Revenues Required Before hVIVO plc (LON:HVO) Stock's 26% Jump Looks Justified
Jan 03At UK£0.20, Is hVIVO plc (LON:HVO) Worth Looking At Closely?
Nov 30A Piece Of The Puzzle Missing From hVIVO plc's (LON:HVO) Share Price
Jun 14A Look At The Intrinsic Value Of hVIVO plc (LON:HVO)
Feb 01Should You Investigate hVIVO plc (LON:HVO) At UK£0.11?
Dec 20Is There An Opportunity With Open Orphan Plc's (LON:ORPH) 41% Undervaluation?
Sep 13Are Investors Undervaluing Open Orphan plc (LON:ORPH) By 44%?
Jun 02Introducing Open Orphan (LON:ORPH), The Stock That Soared 388% In The Last Year
Feb 15How Much Of Open Orphan plc (LON:ORPH) Do Insiders Own?
Dec 23Calculating The Fair Value Of Open Orphan plc (LON:ORPH)
Nov 18Revenue & Expenses Breakdown
How hVIVO makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 24 | 66 | 11 | 0 | 0 |
| 30 Sep 24 | 67 | 14 | 0 | 0 |
| 30 Jun 24 | 67 | 17 | 0 | 0 |
| 31 Mar 24 | 63 | 17 | 0 | 0 |
| 31 Dec 23 | 59 | 16 | 0 | 0 |
| 30 Sep 23 | 60 | 9 | 0 | 0 |
| 30 Jun 23 | 60 | 3 | 0 | 0 |
| 31 Mar 23 | 56 | 1 | 0 | 0 |
| 31 Dec 22 | 51 | -1 | 0 | 0 |
| 30 Sep 22 | 43 | -1 | 0 | 0 |
| 30 Jun 22 | 35 | -1 | 0 | 0 |
| 31 Mar 22 | 37 | -1 | 0 | 0 |
| 31 Dec 21 | 39 | 0 | 0 | 0 |
| 30 Sep 21 | 39 | -2 | 1 | 0 |
| 30 Jun 21 | 39 | -3 | 1 | 0 |
| 31 Mar 21 | 30 | -7 | 1 | 0 |
| 31 Dec 20 | 22 | -11 | 2 | 0 |
| 30 Sep 20 | 16 | -11 | 1 | 0 |
| 30 Jun 20 | 10 | -11 | 1 | 0 |
| 31 Mar 20 | 7 | -8 | 0 | 0 |
| 31 Dec 19 | 3 | -6 | 0 | 0 |
| 30 Jun 19 | 0 | -2 | 0 | 0 |
| 31 Mar 19 | 0 | -1 | 0 | 0 |
Quality Earnings: HVO has high quality earnings.
Growing Profit Margin: HVO's current net profit margins (16.1%) are lower than last year (27.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HVO has become profitable over the past 5 years, growing earnings by 77% per year.
Accelerating Growth: HVO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: HVO had negative earnings growth (-33.9%) over the past year, making it difficult to compare to the Life Sciences industry average (-0.7%).
Return on Equity
High ROE: HVO's Return on Equity (23.8%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/14 09:17 |
| End of Day Share Price | 2025/05/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
hVIVO plc is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Simms | Arden Partners Plc. |
| Michael Mitchell | Cavendish |
| Edward Thomason | CGS International |